Teijin's headline number for the quarter to June 2026 is jarring: net profit attributable to shareholders came in at ¥45.1bn, matching almost exactly the ¥45.0bn the materials and healthcare group told investors it expects to earn for the entire year to March 2027. The reason has little to do with ordinary trading. Teijin completed the sale of its stake in DuPont Teijin Advanced Papers, including the affiliate's Asian unit, to DuPont de Nemours, Inc. during the quarter, booking a ¥45.5bn gain on the disposal. A further ¥5.0bn came from a separate sale of fixed assets, including idle land.
Strip those one-off items out and the underlying business looks steadier but far less dramatic. Revenue fell 8.7% year-on-year to ¥221.9bn, primarily because Teijin no longer consolidates the North American composite-materials business it sold. The paper venture behind the quarter's gain, DuPont Teijin Advanced Papers and its Asian affiliate, was already held as an equity-method investment rather than a consolidated subsidiary, so its disposal shows up as a share sale rather than a swing in reported revenue. Operating profit still leapt to ¥60.0bn from ¥2.3bn a year earlier, almost entirely on the back of the one-off gains. Business profit, Teijin's preferred measure that strips out non-recurring items, rose a more modest 56.8% to ¥12.3bn.
| Metric | Q1 to June 2026 | Q1 to June 2025 | Full-year forecast (to March 2027) |
|---|---|---|---|
| Revenue | ¥221.9bn | ¥243.1bn | ¥900.0bn |
| Operating profit | ¥60.0bn | ¥2.3bn | ¥70.0bn |
| Business profit | ¥12.3bn | ¥7.8bn | ¥30.0bn |
| Net profit (parent) | ¥45.1bn | -¥0.7bn | ¥45.0bn |
| Dividend per share | — | — | ¥50 (¥25 interim / ¥25 year-end) |
Within that, Electronics & Energy was the strongest operating segment, with business profit up 67.7% to ¥8.5bn from ¥5.1bn on steady demand for battery materials and semiconductor-related products. Specialty Materials, which covers aramid and carbon fibre, stayed in the red at a ¥1.0bn loss, though that was narrower than the ¥1.8bn loss a year earlier as plant utilisation improved.
Management left its full-year targets for business profit (¥30.0bn) and operating profit (¥70.0bn) unchanged despite the quarterly surge, and raised the full-year revenue forecast by ¥50.0bn from its previous guidance, to ¥900.0bn. The annual dividend stays at ¥50 per share, split evenly between an interim and a year-end payment. That combination tells its own story: Teijin does not expect its core materials, chemicals, and healthcare operations to repeat the quarter's profit level once the paper-sale gain drops out of the numbers.
The same disclosure flagged a separate restructuring move. Teijin completed the transfer of sales and marketing rights for seven long-listed pharmaceutical products to LTL Pharma Co., Ltd. The products generated roughly ¥12.0bn in sales during the year to March 2026. Teijin says the move lets its in-house pharmaceutical business concentrate on rare-disease and intractable-disease treatments alongside its home healthcare equipment lines.
Teijin also reorganised its reporting structure this quarter, replacing its old three-way split of Materials, Fibres & Products, and Healthcare with four segments: Apparel & Industries, Healthcare & Life Solutions, Electronics & Energy, and Specialty Materials. The balance sheet strengthened on the sale proceeds too, with equity attributable to shareholders rising to ¥415.1bn from ¥364.5bn and the equity ratio improving to 43.7% from 39.6%. The quarterly financial statements attached to this filing have not been reviewed by an outside auditor, according to the disclosure.